With the New Year fast approaching, resolutions for improvement are on everyone’s minds. If cleaner claims for faster reimbursement are at the top of your healthcare organization’s wish list, 2018 may be the perfect time to consider making a claims clearinghouse change. If your claims first pass rate is less than 99.6%, then your claims processing may be hindered by an under-performing editing [...]
Centers for Medicare and Medicaid Services (CMS) published its final rule with comment period revising the Medicare Hospital Outpatient Prospective Payment System (OPPS) for 2018. Labs that provide services to hospital outpatients may want to review the new OPPS rule changes, particularly the revisions to the laboratory date of service (DOS) policy (see CMS excerpt highlighted below).
The financial impact of PAMA to your laboratory depends largely on the type of testing you perform. With the recent publication of the 2018 Medicare CLFS reimbursement rates, it is clear that high-volume clinical laboratory testing is facing substantial downward pricing pressure while much of the advanced molecular diagnostics and genomic testing market reimbursement is neutral to positive. [...]
In the face of PAMA’s substantial cuts to the Part B Clinical Laboratory Fee Schedule (CLFS) on January 1, 2018, many hospitals are reassessing the value proposition of their laboratory service offering.
As the season for giving thanks is upon us, the question heard most often is, “What are you thankful for?” While the usual responses - family, friends, and health - are no doubt significant, it did give us pause to ask ourselves; what is Quadax thankful for?